10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Andreas Neubauer, Martina Crysandt et al.|The Lancet Haematology|2023Cited by 39
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michael Lübbert, Michal Kiciński et al.|Blood|2024Cited by 18
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SGFabio Efficace, Michael Luebbert, Gerwin Huls et al.|Blood|2022Cited by 3
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study groupMichael Lübbert, Gerwin Huls, Pierre W. Wijermans et al.|Blood|2025Cited by 1